1006-34-4

Basic information

• Product Name: 2-Bromo-5-fluorobenzamide
• Synonyms: Benzamide, 2-bromo-5-fluoro-
• CAS NO: 1006-34-4
• Molecular Formula: C₇H₅BrFNO
• Molecular Weight: 218.02
• Product Categories: blocks;Bromides;Carboxes
• Mol File: 1006-34-4.mol

Chemical Properties

• Boiling Point: 249.8°C at 760 mmHg
• Flash Point: 104.9°C
• Appearance: /
• Density: 1.696g/cm³
• Vapor Pressure: 0.0225mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-Bromo-5-fluorobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-5-fluorobenzamide(1006-34-4)
• EPA Substance Registry System: 2-Bromo-5-fluorobenzamide(1006-34-4)

Safety Data

• Hazardous Substances Data: 1006-34-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
2-Bromo-5-fluorobenzamide is used as a reagent in chemical reactions for the synthesis of more complex organic molecules. Its presence of bromine and fluorine atoms on the benzene ring allows for versatile chemical transformations, making it a valuable building block in the creation of advanced organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-Bromo-5-fluorobenzamide is utilized as an intermediate in the synthesis of pharmaceuticals. Its unique structure and functional groups contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemicals:
2-Bromo-5-fluorobenzamide also finds applications in the agrochemical industry, where it serves as an intermediate in the synthesis of agrochemicals. Its properties can be harnessed to develop new pesticides or herbicides with improved efficacy and selectivity.
Used in Drug Discovery and Development:
Due to its potential biological and pharmacological activities, 2-Bromo-5-fluorobenzamide is a subject of interest for researchers studying its potential use in drug discovery and development. Its unique structure and functional groups may contribute to the development of new therapeutic agents with novel mechanisms of action.

InChI:InChI=1/C7H5BrFNO/c8-6-2-1-4(9)3-5(6)7(10)11/h1-3H,(H2,10,11)

Upstream product

• 111771-13-2 2-bromo-4-fluorobenzoyl chloride 
• 394-28-5 2-Bromo-5-fluorobenzoic acid 
• 33184-16-6 5-fluoro-2-methylbenzoic acid 
• 57381-39-2 2-bromo-5-fluorobenzonitrile 

Downstream Products

• 67-56-1 methanol 
• 1021539-61-6 C₂₆H₂₁F₂N₃O₂ 
• 1425605-95-3 7-fluoro-3-phenylisoquinolin-1-amine 
• 1425606-02-5 7-fluoro-3-(4-methoxyphenyl)isoquinolin-1-amine 
• 371945-79-8 6-fluoro-2-phenyl-3H,4H-quinazolin-4-one 
• 1425605-66-8 5-fluoro-2-((4-methoxyphenyl)ethynyl)benzamide 
• 1338797-90-2 5-fluoro-2-(phenylethynyl)benzamide 
• 1207252-46-7 5-fluoro-2-(hex-1-ynyl)benzamide 
• 1255775-75-7 5-fluoro-2-(5-hydroxypent-1-ynyl)benzamide 

Relevant articles and documents

Discovery of highly potent SARS-CoV-2 Mpro inhibitors based on benzoisothiazolone scaffold

The COVID-19 pandemic has drastically impacted global economies and public health. Although vaccine development has been successful, it was not sufficient against more infectious mutant strains including the Delta variant indicating a need for alternative treatment strategies such as small molecular compound development. In this work, a series of SARS-CoV-2 main protease (Mpro) inhibitors were designed and tested based on the active compound from high-throughput diverse compound library screens. The most efficacious compound (16b-3) displayed potent SARS-CoV-2 Mpro inhibition with an IC50 value of 116 nM and selectivity against SARS-CoV-2 Mpro when compared to PLpro and RdRp. This new class of compounds could be used as potential leads for further optimization in anti COVID-19 drug discovery.

Substrate Profiling of the Cobalt Nitrile Hydratase from Rhodococcus rhodochrous ATCC BAA 870

The aromatic substrate profile of the cobalt nitrile hydratase from Rhodococcus rhodochrous ATCC BAA 870 was evaluated against a wide range of nitrile containing compounds (>60). To determine the substrate limits of this enzyme, compounds ranging in size from small (90 Da) to large (325 Da) were evaluated. Larger compounds included those with a biaryl axis, prepared by the Suzuki coupling reaction, Morita–Baylis–Hillman adducts, heteroatomlinked diarylpyridines prepared by Buchwald–Hartwig crosscoupling reactions and imidazo[1,2a]pyridines prepared by the Groebke–Blackburn–Bienaymé multicomponent reaction. The enzyme active site was moderately accommodating, accepting almost all of the small aromatic nitriles, the diarylpyridines and most of the biaryl compounds and Morita–Baylis–Hillman products but not the Groebke–Blackburn–Bienaymé products. Nitrile conversion was influenced by steric hindrance around the cyano group, the presence of electron donating groups (e.g., methoxy) on the aromatic ring, and the overall size of the compound.

Synthesis of 1-aminoisoquinolines by gold(III)-mediated domino reactions from 2-alkynylbenzamides and ammonium acetate

A facile synthetic route toward pharmaceutically interesting 1-aminoisoquinoline derivatives by gold(III)-mediated domino reactions is described. This synthetic protocol starts from readily available 2-alkynylbenzamides and ammonium acetate and takes plac

PROCESS FOR MAKING GLUCOCORTICOID RECEPTOR LIGANDS

The invention encompasses a process for making 2-[1-phenyl-5-hydroxy-4alpha-methyl-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives, which are glucocorticoid receptor ligands, useful for the treatment of inflammatory and immunological diseases.

2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS

The present invention is directed to 2- [l-phenyl-5 -hydroxy or methoxy-4alpha- methyl-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives of formula I (I) as glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflamma

HIV integrase inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.